New Phase 3 trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer — Genmab

10 SOURCES CONFIRMED · FIRST SEEN 2026-10-05 12:00 UTC · LAST UPDATE 2026-10-05 13:15 UTC

KINDCompany

DIRECTION■ Unclear/unknown

SOURCES10

ENTITIES1

STORY SIZE10 RECORDS

FIRST SEEN2026-10-05 12:00 UTC

LAST UPDATE2026-10-05 13:15 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Genmab's Rina-S ovarian cancer trial could expand its oncology franchise if data support standard-of-care combination.

Genmab tests Rina-S in ovarian cancer

CATALYST TO WATCH

Enrollment start or interim efficacy

MAIN RISK

Not-yet-recruiting, competitive space

FULL DISPATCH

Sponsor: Genmab; Status: Not Yet Recruiting; Conditions: Ovarian Cancer; Interventions: Rina-S, Bevacizumab; Enrollment: 602 (estimated); First posted: 2026-10-05; NCT: NCT07859215

02 THE STORY SO FAR

THE RECORD, IN ORDER.

UPDATED 10 TIMES · FIRST 2026-10-05 12:00 UTC · LAST 2026-10-05 13:15 UTC

2026-10-05 12:00 UTCCompanyNew Phase 3 trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer — GenmabCURRENT RECORD

2026-10-05 12:00 UTCCompanyNew Phase 3 trial: Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1 — Ambros Therapeutics, Inc.

2026-10-05 12:00 UTCCompanyNew Phase 3 trial: A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera — Agios Pharmaceuticals, Inc.

2026-10-05 12:00 UTCCompanyNew Phase 3 trial: Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma — Chiesi Farmaceutici S.p.A.

2026-10-05 12:00 UTCCompanyNew Phase 3 trial: The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505. — GL Pharm Tech Corporation

2026-10-05 12:00 UTCCompanyPhase 3 results posted: Lumateperone for the Prevention of Relapse in Patients With Schizophrenia — Intra-Cellular Therapies, Inc.

2026-10-05 12:00 UTCCompanyPhase 3 results posted: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease — Incyte Corporation

2026-10-05 12:45 UTCNewsOMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.

2026-10-05 13:10 UTCNewsROXUS® RISES TO THE OCCASION WITH THE NEXT GENERATION OF RAPID-ACTING INTRANASAL PDE-5 TREATMENT

2026-10-05 13:15 UTCNewsCellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development

03 WHO'S INVOLVED